TRAVELLER
The TRAVELLER study is a standalone master pre-screening study which aims to collect information, including blood-based biomarker data and limited cognitive assessments, to help identify individuals who may be suitable for current or future Roche Alzheimer's disease clinical trials.
Participants do not receive any investigational treatment or medicinal product as part of this study.
This study has been approved by Bellberry Limited (Application No: 2025-03-348)
Participation
People aged 50 -90 years inclusive and who are willing to participant in a clinical study are invited to participate in the TRAVELLER study.
Information gathered through participation in the TRAVELLER study may assist in determining whether a participant could be eligible for another Roche study either now or in the future.
Participation in TRAVELLER does not guarantee eligibility for another study, and participants are under no obligation to take part in any future clinical trial they may be identified as suitable for.
Participant duration
2-3 visits
Available to people living in
NSW
Study begins
Thursday, 1 October 2026
Study ends
Friday, 1 October 2027
Contact
To find out more about this study, contact:
Lisa Swan
KaRa Institute of Neurological Diseases
13-15 Lyonpark Road Macquarie Park NSW 2113 , NSW
